Schedule V
HRS §329-22
in effect329-22. Schedule V
(a) The controlled substances listed in this section are included in schedule V.
(b) Narcotic drugs containing nonnarcotic
active medicinal ingredients. Any compound, mixture, or preparation containing
limited quantities of any of the following narcotic drugs, which also contains
one or more nonnarcotic active medicinal ingredients in sufficient proportion
to confer upon the compound, mixture, or preparation, valuable medicinal
qualities other than those possessed by the narcotic drug alone:
(1) Not more than 200 milligrams of codeine, or any
of its salts, per 100 milliliters or per 100 grams;
(2) Not more than 100 milligrams of dihydrocodeine,
or any of its salts, per 100 milliliters or per 100 grams;
(3) Not more than 100 milligrams of ethylmorphine, or
any of its salts, per 100 milliliters or per 100 grams;
(4) Not more than 2.5 milligrams of diphenoxylate and
not less than 25 micrograms of atropine sulfate per dosage unit;
(5) Not more than 100 milligrams of opium per 100
milliliters or per 100 grams; and
(6) Not more than 0.5 milligram of difenoxin and not
less than 25 micrograms of atropine sulfate per dosage unit.
(c) Stimulants. Unless specifically exempted
or excluded or unless listed in another schedule, any material, compound,
mixture, or preparation that contains any quantity of the following substances
having a stimulant effect on the central nervous system, including its salts,
isomers, and salts of isomers.
(d) Depressants. Unless specifically exempted
or excluded or unless listed in another schedule, any material, compound,
mixture, or preparation that contains any quantity of the following substances
having a depressant effect on the central nervous system, including its salts,
isomers, and salts of isomers:
(1) Brivaracetam
((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (Other names: BRV;
UCB-34714; Briviact) and its salts;
(2) Ganaxolone
(3[alpha]-hydroxy-3[beta]-methyl-5[alpha]-pregnan-20-one);
(3) Lacosamide
[(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide], (Vimpat);
(4) Lasmiditan
(2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide);
and
(5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
acid].
[L 1972, c 10, pt of §1; am L 1978, c 68, §6; am L 1985, c 150, §4; am L
2003, c 151, §6; am L 2008, c 119, §6; am L 2010, c 123, §4; am L 2017, c 155,
§3; am L 2019, c 95, §1; am L 2021, c 233, §4; am L 2022, c 106, §4; am L 2023,
c 162, §3]
Source: Hawaii State Legislature (capitol.hawaii.gov), via Internet Archive capturesURL: http://www.capitol.hawaii.gov/hrscurrent/Vol06_Ch0321-0344/HRS0329/HRS_0329-0022.htmFetched: 11/10/2026